Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Hemophilia B, or factor IX deficiency, is an X-linked recessive disorder occurring in about 1 in 25,000 males. Affected individuals are at risk for spontaneous bleeding into many organs; treatment mainly consists of the transfusion of clotting factor concentrates prepared from human blood or recombinant sources after bleeding has started. Small- and large-animal models have been developed and/or characterized that closely mimic the human disease state. As a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B, respectively. There was no associated toxicity with infusion in either animal model. Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice. Mice with a steady-state concentration of 25% of the normal human level of factor IX had normal coagulation. In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
In the citing paper
“Capsid-specific T cell responses to AAV-based therapies were not predicted from proof-of-concept studies in animal models but were identified in human studies.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
Citations
Cites
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Samulski, R. J., Chang, L. S., & Shenk, T. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3822-3828.1989 · Cited by 743
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells
Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J., & Muzyczka, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4646-4654.1996 · Cited by 609
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593
Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., & Verma, I. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1401 · Cited by 591
Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
Smith, T. A. G., Mehaffey, M. G., Kayda, D. B., Saunders, J. M., Yei, S., Trapnell, B. C., McClelland, A., & Kaleko, M. (1993) · Nature Genetics · doi:10.1038/ng1293-397 · Cited by 335
Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., et al. (1998) · Blood · doi:10.1182/blood.v92.1.68.413k23_68_75 · Cited by 304
In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs
Kay, M. A., Rothenberg, S., Landen, C. N., Bellinger, D. A., Leland, F., Toman, C., Finegold, M., Thompson, A. R., Read, M. S., Brinkhous, K. M., et al. (1993) · Science · doi:10.1126/science.8211118 · Cited by 304
Self-citation
Research works printed but not linked: 2
- Brinkhous, K.M. et al. Pharmacokinetics and pharmacodynamics of a B-domain deleted recombinant factor VIII derivative, r-VIII SQ, in canine hemophilia. Thromb. Haemost. 69, 852 (1993 ).
- Brinkhous, K.M., Landen, C.N. & Read, M.S. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F.IX one-stage bioassay tests with low plasma F.IX levels observed with transfusion or gene therapy in canine hemophilia B. Blood 82, suppl 1 :592a (1993).
Cited by
Items 301–400 of 429
Correction of genetic blood defects by gene transfer
Cavazzana, M., & Hacein‐Bey‐Abina, S. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200111000-00008 · Cited by 15
Dix ans de thérapie génique: Déceptions et espoirs
Kahn, A. (2000) · Biofutur · doi:10.1016/s0294-3506(00)80020-4 · Cited by 14
Hemophilia gene therapy: Update
Monahan, P. E., & White, G. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200209000-00007 · Cited by 14
Mimuro, J., Muramatsu, S., HAKAMADA, Y., Mori, K., Kikuchi, J., Urabe, M., Madoiwa, S., OZAWA, K., & Sakata, Y. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301579 · Cited by 14
Identification of the murine AAVrh32.33 capsid-specific CD8+ T cell epitopes
Mays, L. E., & Wilson, J. M. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1402 · Cited by 13
Portal Vein Delivery of Viral Vectors for Gene Therapy for Hemophilia
Sherman, A., Schlachterman, A., Cooper, M., Merricks, E. P., Raymer, R. A., Bellinger, D. A., Herzog, R. W., & Nichols, T. C. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-761-7_27 · Cited by 13
Self-citationNguyen, T. H., & Ferry, N. (2007) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.1.1.155 · Cited by 13
MOLECULAR THERAPEUTICS OF LIVER DISEASE
Davern, T. J. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70171-9 · Cited by 13
Gene therapy for bleeding disorders
Manno, C. S. (2002) · Current Opinion in Hematology · doi:10.1097/00062752-200211000-00008 · Cited by 13
Bergmann, T., Ehrke‐Schulz, E., Gao, J. J., Schiwon, M., Schildgen, V., Dávid, S., Schildgen, O., & Ehrhardt, A. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3020 · Cited by 12
Gene therapy for lipid disorders
Kawashiri, M., & Rader, D. J. (2000) · Trials · doi:10.1186/cvm-1-2-120 · Cited by 12
Applications of genetic engineering in veterinary medicine
Çiftçi, K., & Trovitch, P. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00077-6 · Cited by 11
Gene‐Based Approaches to the Treatment of Hemophilia
High, K. A. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb03050.x · Cited by 11
Biotechnology: alternatives to human plasma-derived therapeutic proteins
Lynch, T. J. (2000) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2000.0100 · Cited by 11
Gene therapy for the haemophilias
Thompson (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00055.x · Cited by 11
Logan, G. J., de Alencastro, G., Alexander, I. E., & Yeoh, G. C. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.10.023 · Cited by 10
Gene therapy for the hemophilias
Walsh, C. (2002) · Current Opinion in Pediatrics · doi:10.1097/00008480-200202000-00003 · Cited by 10
A New Potent hFIX Plasmid for Hemophilia B Gene Therapy
Lee, J. S., Lee, M., & Kim, S. W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000033010.96920.33 · Cited by 9
Hahnewald, R., Wegner, W., & Reiss, J. (2009) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-7-9 · Cited by 9
Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium
Scimia, M. C., Cannavò, A., & Koch, W. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.818813 · Cited by 9
Development of Targeted Viral Vectors for Cardiovascular Gene Therapy
Nicklin, S. A., & Baker, A. H. (2003) · Springer eBooks · doi:10.1007/978-1-4615-0073-5_2 · Cited by 9
Gene therapy for dyslipidemia: Clinical prospects
Rader, D. J., & Tietge, U. J. F. (1999) · Current Atherosclerosis Reports · doi:10.1007/s11883-999-0051-5 · Cited by 8
Somatic gene therapy for dyslipidemias
Belalcazar, M., & Chan, L. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90199-3 · Cited by 8
Collis, S. J., Khater, K., & DeWeese, T. L. (2003) · World Journal of Urology · doi:10.1007/s00345-003-0363-y · Cited by 8
Rajapaksha, I. G., Angus, P., & Herath, C. B. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80317 · Cited by 7
Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia
Hedner, U. K. E., Ginsburg, D., Lusher, J. M., & High, K. A. (2000) · Hematology · doi:10.1182/asheducation.v2000.1.241.20000241 · Cited by 7
Adeno‐associated viral vectors for gene therapy
Flotte, T. R., & Berns, K. I. (2005) · Laboratory techniques in biochemistry and molecular biology · doi:10.1016/s0075-7535(05)31001-1 · Cited by 7
Specific detection of human coagulation factor IX in cynomolgus macaques
Mimuro, J., Mizukami, H., Ono, F., Madoiwa, S., Terao, K., Yoshioka, A., OZAWA, K., & Sakata, Y. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7933.2003.00572.x · Cited by 7
Assignation of highly polymorphic markers on a canine purebred pedigree
Tiret, L., Kessler, J.-L., Bentolila, S., Fauré, S., Bach, J., Weissenbach, J., & Panthier, J. (2000) · Mammalian Genome · doi:10.1007/s003350010143 · Cited by 7
Ozawa, K. (2007) · Uirusu · doi:10.2222/jsv.57.47 · Cited by 6
Artemyev, V., Paremskaia, A. I., Dzhioeva, A. A., Mishina, D., Bogdanov, V. P., Krupinova, J. A., Mazloum, A., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2025) · Cells · doi:10.3390/cells15010014 · Cited by 4
Gene Therapy for Hemophilia: A Step Closer to Reality
White, G., & Roberts, H. R. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0048 · Cited by 4
Gene therapy using AAV vectors
Ozawa, K. (2007) · Drug Delivery System · doi:10.2745/dds.22.643 · Cited by 4
Mechanisms of Unresponsiveness:T- And B-Cell Mediated Mechanisms of Anergy
Greenwood, R., & Frelinger, J. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-1277-6_10 · Cited by 4
Haemophilias: advances towards genetic engineering replacement therapy
Emilien, G., Maloteaux, J. M., Penasse, C., Goodeve, A. C., & Casimir, C. M. (2000) · Clinical & Laboratory Haematology · doi:10.1046/j.1365-2257.2000.00332.x · Cited by 4
Podevin, G., Pichard, V., Durand, S., Aubert, D., Héloury, Y., & Ferry, N. (2002) · Pediatric Surgery International · doi:10.1007/s00383-002-0864-6 · Cited by 4
Thérapie génique du déficit immunitaire combiné sévère lié à l'X (DICS-X1)
Hacein‐Bey‐Abina, S., Gross, F., Nusbaum, P., Yvon, E. S., Fischer, A., & Cavazzana, M. (2001) · Pathologie Biologie · doi:10.1016/s0369-8114(00)00002-x · Cited by 3
Efa, B., Tiesjema, B., Jch, V. E., Hermsen, H. P. H., Sir, ., & Bmt (2008) · Rivm Repository (Netherlands National Institute for Public Health and the Environment) · Cited by 3
Nakai, H. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_23 · Cited by 3
Lu, H., Chen, L., Wang, H., Wu, Z., Wu, X., Wang, X., Wang, H., Daru, L., Qiu, X., & Xue, J. (2001) · Science in China Series C Life Sciences · doi:10.1007/bf02879352 · Cited by 3
Using Endothelial Progenitor Cells for Gene Therapy
Pearson, J. D. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000106319.61386.e1 · Cited by 3
Immune tolerance in hemophilia and treatment of hemophiliacs with an inhibitor.
Mariani, G., & Brackmann, H. (2001) · PubMed · Cited by 3
Bioengineering prospects in livestock production
Singh, A. P., Shrivastava, K., Hagos, T. H., & Pandey, H. O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-98385-3.00001-3 · Cited by 2
Perioperative haemostatic management of haemophilic mice using normal mouse plasma
Tatsumi, K., Ohashi, K., Kanegae, K., Shim, I. K., & Okano, T. (2013) · Haemophilia · doi:10.1111/hae.12211 · Cited by 2
Kozarsky, K. (1999) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1310s22 · Cited by 2
Gene Therapy for Von Willebrand Disease
Chuah, M., Petrus, I., & VandenDriessche, T. (2011) · Wiley eBooks · doi:10.1002/9781444329926.ch20 · Cited by 2
Shangaris, P., & David, A. L. (2016) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4939-3483-6_19 · Cited by 2
Aproximaciones de terapia génica para la diabetes tipo 1
Ayuso, E., Mann, C., Anguela, X. M., & Bosch, F. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)61002-2 · Cited by 2
Recombinant adeno-associated virus vectors for somatic gene therapy in dermatology
Braun‐Falco, M., & Roedl, D. (2007) · Expert Review of Dermatology · doi:10.1586/17469872.2.2.167 · Cited by 2
Robbins, P. D., Storkus, W. J., & Gambotto, A. A. (2003) · Elsevier eBooks · doi:10.1016/b978-012689663-3/50063-6 · Cited by 2
Callaghan, M. U., & Kaufman, R. J. (2009) · Wiley eBooks · doi:10.1002/9780470015902.a0005750.pub2 · Cited by 2
Gene Therapy for Metabolic Diseases of the Liver
Promrat, K., Wu, G. Y., & Wu, C. H. (2000) · BioDrugs · doi:10.2165/00063030-200013030-00003 · Cited by 2
Therapeutic approaches for haemophilia
Hortelano, G., & Ofosu, F. A. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.6.929 · Cited by 2
Neyns, B., Vermeij, J., Teugels, E., Rycke, M. D., Hermonat, P. L., & Grève, J. D. (2001) · Intervirology · doi:10.1159/000050056 · Cited by 2
GENE THERAPY FOR T-CELL IMMUNODEFICIENCIES
Kohn, D. B., Weinberg, K. I., & Parkman, R. (2000) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(05)70143-0 · Cited by 2
Pompe Disease-Glycogenosis Type II: Acid Maltase Deficiency
Reuser, A. J. J., & Kroos, M. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-70909-3_30 · Cited by 2
Adeno-associated viral vector gene therapy for canine hemophilia
Crudele, J. M., Doshi, B. S., & Callan, M. B. (2026) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.66 · Cited by 1
Lu, H., Chen, L., Wang, X., Lu, D., Qiu, X., & Xue, J. (2001) · Chinese Science Bulletin · doi:10.1007/bf03183391 · Cited by 1
Lessons Learned from Animal Models of Inherited Bleeding Disorders.
Nichols, T. C. (2014) · PubMed · Cited by 1
Self-citationSurbek, D., Wagner, A. M., & Schoeberlein, A. (2009) · Wiley eBooks · doi:10.1002/9780470480151.ch4 · Cited by 1
Artificial cells as a novel approach to gene therapy
Potter, M., Li, A. A., Cirone, P., Shen, F., & Chang, P. L. (2007) · Elsevier eBooks · doi:10.1533/9781845693077.3.236 · Cited by 1
State of the art on clinical trials of gene therapy in haemophilia
Garagiola, I., & Peyvandi, F. (2020) · doi:10.36118/pharmadvances.03.2020.05 · Cited by 1
Adeno-Associated Virus: A Promising Tool for Gene Delivery
Douar, A. M. (2000) · Cell engineering · doi:10.1007/978-94-011-4315-8_6 · Cited by 1
Huttner, N. A. (2003) · doi:10.5282/edoc.1420 · Cited by 1
Reshaping AAV vectors for liver gene therapy
Kühnel, F., & Kubicka, S. (2008) · Hepatology · doi:10.1002/hep.22590 · Cited by 1
IMPROVED MUTATION DETECTION FOR HAEMOPHILIA A IN SOUTH AFRICA
Mitchell, C. L. (2009) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg) · Cited by 1
Thérapie génique des maladies héréditaires du foie
Ferry, N. (1999) · Annales de l Institut Pasteur / Actualités · doi:10.1016/s0924-4204(00)80005-0 · Cited by 1
Kankkonen, H. M. (2004) · UEF eRepo (University of Eastern Finland) · Cited by 1
Vectors for Gene Transfer to Joints
Robbins, P. D., Ghivizzani, S. C., Glorioso, J. C., & Evans, C. H. (2000) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-2126-5_14 · Cited by 1
Gene therapy using AAV (adeno-associated virus) vectors
Ozawa, K. (2003) · Uirusu · doi:10.2222/jsv.53.163 · Cited by 1
Bello, A. J. A. (2014) · Mspace (University of Manitoba) · Cited by 1
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f · Cited by 1
Watzke, H. (2001) · Der Internist · doi:10.1007/s001080170058
Gene Therapy of Haemopoietic Disorders
Rousseau, R. F., & Brenner, M. K. (2005) · Wiley eBooks · doi:10.1002/9780470987056.ch27
Kaufman, R. J. (2006) · Wiley eBooks · doi:10.1038/npg.els.0005750
Badowski, M. (2009) · UA Campus Repository (The University of Arizona)
35. Downregulation of Immune Responses Induced by Oral DNA Administration
(2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.059
Gene therapy: physiological principles and clinical potential
Mehta, V., & David, A. L. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511997778.043
Genetic manipulation of the pancreas: cell and gene therapy approaches for type 1 diabetes
Ayuso, E. (2006) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Adenovirus-based gene therapy approaches for hemophilia B
Zhang, W. (2012) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.14566
The Use of Skin-Directed Gene Therapy in the Treatment of Systemic Diseases
Jensen, T. G., & Csaky, K. G. (2001) · Springer eBooks · doi:10.1007/978-3-642-56441-3_9
CLINICAL DEVELOPMENT OF AAV VECTORS
Carter, B. J. (2010) · Gene Therapy and Regulation · doi:10.1142/s1568558610000215
Treatment of Hemophilia With Genetic Engineering
Axsom, K., & Manno, C. S. (2004) · Transfusion Alternatives in Transfusion Medicine · doi:10.1111/j.1778-428x.2004.tb00117.x
Viral-vectored ribozymes as therapy for autosomal dominant retinal disease
Hauswirth, W. W., LaVail, M. M., Flannery, J. G., & Lewin, A. S. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(00)00010-4
AAV immunity: more than meets the eye
Lillicrap, D. (2006) · Blood · doi:10.1182/blood-2005-12-4921
335. Correction of a Murine Model of Von Willebrand Disease by Gene Transfer
(2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.338
Yu, C.-Y., Wang, B., Wang, Z., Cao, Z., Li, J., & Xiao, X. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.556
FVIII Immunity: Early Events and Tolerance Mechanisms to FVIII
Qadura, M. (2008) · QSpace (Queen's University Library)
重组腺相关病毒(rAAV)介导的人凝血因子Ⅸ高活性突变衍生物在血友病B基因治疗研究中的应用
陆华中, 陈立, 王红卫, 伍志坚, 吴小兵, 王学峰, 王鸿利, 卢大儒, 邱信芳, & 薛京伦 (2001) · Science in China Series C-Life Sciences (in Chinese) · doi:10.1360/zc2001-31-6-523
14 for Gene Transfer to Joints
Robbins, P. D., Ghivizzani, S. C., Glorioso, J. C., & Evans, C. H. (2000)
Site-directed integration using the Cre/lox system in hematopoietic and embryonic stem cells
Faulkes, S. (2009) · cIRcle (University of British Columbia) · doi:10.14288/1.0090532
Current Status and Future Prospects of Gene Therapy.
Ozawa, K. (1999) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.36.690
Recent Advances in Gene Therapy of Hemophilia B.
Shima, M. (1999) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.10.310
Thérapie génique de la douleur
Pohl, M., & Bráz, J. M. (2001) · Douleur et Analgésie · doi:10.1007/bf03012693
Gene therapy for haemophilia: an update on progress in clinical trials
Gilgunn, S. (2015) · The Journal of Haemophilia Practice · doi:10.17225/jhp.00039
New somatic transgenic mouse models in transthyretin amyloidosis: from pathogenesis to gene therapy
Batista, A. R. D. S. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/p4ac-7f74
한대종 (2003) · YUHSpace (Yonsei University Medical Library)
Adeno-Associated Virus-Based Vectors
Dutheil, N., & Bézard, E. (2013) · Neuromethods · doi:10.1007/978-1-62703-610-8_3
Metadata
- Authors
- Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., Read, M. S., Bellinger, D. A., Brinkhous, K. M., & Kay, M. A.
- Affiliations
- University of Washington (US)
- Stanford Medicine (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Medicine
- Published
- 1999-01
- Volume
- 5
- Issue
- 1
- Pages
- 64-70
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- DOI
- 10.1038/4751
- OpenAlex
- W1588659566
- Cited by
- 409
- References
- 30
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2022: 4 · 2021: 1 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 8 · 2012: 12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl001648-50)
- National Heart, Lung, and Blood Institute (HL 53682, R01HL053682, HL-01648)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, adeno-associated virus vectors, gene therapy, canine model, mouse model, liver gene transfer, coagulation correction, X-linked bleeding disorder, vector toxicity
- MeSH terms
- Dependovirus, Animals, Antibodies, Bleeding Time, Cell Transformation, Viral, Hemophilia B, Disease Models, Animal, Dogs, Factor IX, Genetic Vectors, Humans, Liver, Mice, Inbred C57BL, Recombination, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.